0000861838 false 0000861838 2022-06-23 2022-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 23, 2022

 

Idera Pharmaceuticals, Inc. 

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other

Jurisdiction of

Incorporation)

001-31918

(Commission File

Number)

04-3072298

(I.R.S. Employer

Identification No.)

 

505 Eagleview Blvd., Suite 212    
Exton, Pennsylvania   19341
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (484) 348-1600

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

  

Trading

Symbol(s)

  

Name of each

exchange on which registered

Common Stock, par value $0.001 per share   IDRA   Nasdaq Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Contemporary Arrangements of Certain Officers.

 

At the Annual Meeting of Stockholders of Idera Pharmaceuticals, Inc. (the “Company”) held on June 23, 2022 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2022 Stock Plan Amendment”) to the Idera Pharmaceutical, Inc. 2013 Stock Incentive Plan (the “2013 Stock Plan”) for the sole purpose of increasing the number of shares reserved for issuance under the 2013 Stock Plan. Also at the Annual Meeting, the Company’s stockholders approved an amendment (the “2022 ESPP Amendment”) to the Idera Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (the “2017 ESPP”) for the sole purpose of increasing the number of shares authorized for issuance under the 2017 ESPP. Both the 2022 Stock Plan Amendment and the 2022 ESPP Amendment previously had been approved, subject to stockholder approval, by the Board of Directors of the Company (the “Board”) on April 15, 2022.

 

Descriptions of the material terms of each of the 2013 Stock Plan, as amended by the 2022 Stock Plan Amendment, and the 2017 ESPP, as amended by the 2022 ESPP Amendment, can be found in “Proposal 4 – Approval of Amendment to 2013 Stock Incentive Plan” and “Proposal 5 – Approval of Amendment to 2017 Employee Stock Purchase Plan,” respectively, in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2022 (the “2022 Proxy Statement”), which descriptions are incorporated herein by reference.

 

The foregoing descriptions and the descriptions incorporated by reference from the 2022 Proxy Statement are qualified in their entireties by reference to (i) the 2013 Stock Plan, a copy of which is attached as Exhibit 10.1 to the Current Report on Form 8-K filed on June 13, 2014, (ii) the 2022 Stock Plan Amendment, a copy of which is attached hereto as Exhibit 10.1, (iii) the 2017 ESPP, a copy of which is attached as Exhibit 10.2 to the Current Report on Form 8-K filed on June 9, 2017, and (iv) the 2022 ESPP Amendment, a copy of which is attached hereto as Exhibit 10.2, and each of which is incorporated herein by reference.

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting, the Company’s stockholders voted upon the following five proposals, each of which is described in more detail in the 2022 Proxy Statement. The final vote results for each proposal were as follows:

 

Proposal 1: Election of Directors

 

The stockholders elected each of the individuals set forth below to serve as Class III directors on the Board for a three-year term expiring at the Company’s 2025 annual meeting of stockholders:

 

  Shares
For		 Shares
Withheld		 Broker
Non-Votes
Mark Goldberg, M.D. 14,923,142 2,265,194 9,714,893
Carol A. Schafer 16,673,520 514,816 9,714,893

 

Proposal 2: Approval, by Non-Binding Vote, of the Compensation of Named Executive Officers for 2021

 

The stockholders approved a non-binding resolution regarding the compensation of the Company’s named executive officers for 2021, with votes as follows:

 

Shares
For		 Shares
Against		 Shares
Abstained		 Broker
Non-Votes
16,518,494 578,085 91,757 9,714,893

 

 

 

 

Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm

 

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified by the stockholders, with votes as follows:

 

Shares
For		 Shares
Against		 Shares
Abstained		 Broker
Non-Votes
26,347,622 260,455 91,757 0

 

Proposal 4: Approval of Amendment to 2013 Stock Incentive Plan

 

The 2022 Stock Plan Amendment to increase the number of shares reserved for issuance under the 2013 Stock Plan was approved by stockholders, with votes as follows:

 

Shares
For		 Shares
Against		 Shares
Abstained		 Broker
Non-Votes
16,202,765 969,014 16,557 9,714,893

 

Proposal 4: Approval of Amendment to 2017 Employee Stock Purchase Plan

 

The 2022 ESPP Amendment to increase the number of authorized shares reserved for issuance under the 2017 ESPP was approved by stockholders, with votes as follows:

 

Shares
For		 Shares
Against		 Shares
Abstained		 Broker
Non-Votes
16,272,092 901,980 14,264 9,714,893

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

See the Exhibit Index below, which is incorporated by reference herein.

 

Exhibit

 

Number 

  Description
10.1  Amendment to the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan
    
10.2  Amendment to the Idera Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan
    
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IDERA PHARMACEUTICALS, INC.
   
   
  By: /s/ Bryant D. Lim
    Bryant D. Lim
    Senior V.P., General Counsel

 

Dated: June 24, 2022

 

 

 

Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Idera Pharmaceuticals.
Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Idera Pharmaceuticals.